

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>A61K 9/12</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/06783</b> <b>(43) International Publication Date:</b> 27 February 1997 (27.02.97)
<b>(21) International Application Number:</b> PCT/US96/13133 <b>(22) International Filing Date:</b> 13 August 1996 (13.08.96)  <b>(30) Priority Data:</b> 08/516,786 18 August 1995 (18.08.95) US  <b>(71) Applicant:</b> BAKER NORTON PHARMACEUTICALS, INC. [US/US]; 4400 Biscayne Boulevard, Miami, FL 33137 (US).  <b>(72) Inventors:</b> AHMED, Tahir, 1020 South Greenway Drive, Coral Gables, FL 33134 (US). BRODER, Samuel; 759 Heron Road, Ft. Lauderdale, FL 33326 (US). WHISNANT, John, K.; 3040 Birkdale, The Reserve, Ft. Lauderdale, FL 33322 (US).  <b>(74) Agent:</b> SCHIFFMILLER, Martin, W.; Kirschstein, Ottinger, Israel & Schiffmiller, 551 Fifth Avenue, New York, NY 10176 (US).		<b>(81) Designated States:</b> AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> METHOD AND COMPOSITION FOR TREATING ASTHMA  <b>(57) Abstract</b>  A method of treating a patient suffering from antigen-induced asthma who has been challenged with an antigen, or providing chronic treatment to an asthma patient to reduce airway hyperresponsiveness, comprising intrabronchial administration to the patient of a pharmaceutical composition containing in each dose about 0.05 to about 1.0 mg of ultra-low molecular weight heparins (ULMWH), having an average molecular weight of 3,000 daltons or less, per kilogram of patient body weight. Inhalant pharmaceutical compositions for use in the novel treatment method are also provided.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## METHOD AND COMPOSITION FOR TREATING ASTHMA

This application incorporates material included in Disclosure Document No. 377066, filed in the Patent and Trademark Office on June 23, 1995.

The invention relates to methods and compositions for preventing and reversing the symptoms and manifestations of asthma.

Chronic asthma can be considered to be predominantly an inflammatory disease with associated bronchospasm. The degree of reactivity and narrowing of the bronchi in response to stimuli is greater in asthmatics than in normal individuals. Persistent inflammation is responsible for the bronchial hyperreactivity or airway hyperresponsiveness. Mucosal edema and mucus plugging and hypersecretion may be present; pulmonary parenchyma is normal. Airway narrowing may reverse spontaneously or with therapy. Type 1 (immediate) immune responses may play an important role in the development of asthma in children and many adults; however, when onset of disease occurs in adulthood, allergic factors may be difficult to identify. Exposure to cold dry air, exercise and other aggravating factors also may trigger asthma.

The most common symptoms of asthma are breathlessness and chest tightness; wheezing, dyspnea, and cough also are prominent. Reduced pulmonary function typical of obstructive rather than restrictive airway disease is usually observed. Asymptomatic periods often alternate with paroxysms.

Of the known triggers of asthma, allergens and exercise have received the most attention. Both are powerful, naturally occurring stimuli; exercise is a potential factor in the daily life of every asthmatic, whereas allergens only affect some persons with asthma. Nevertheless, more is known about the effects of antigen.

The general goals of drug therapy for asthma are prevention of bronchospasm and long-term control of bronchial hyperreactivity. Because it is usually not possible for either patient or physician to predict when bronchospasm may occur, patients with all but the most episodic and/or entirely seasonal attacks may require continuous therapy.

Beta agonists are useful as bronchodilator agents; they stimulate beta<sub>2</sub>-adrenergic receptors, increase intracellular cAMP, and may inhibit the release of mast cell mediators. Other useful drugs include theophylline and related xanthine drugs, which produce bronchodilation through unknown mechanisms; the bismomone, cromolyn, which prevents the release of mediator substances and blocks respiratory neuronal reflexes, and corticosteroids, which primarily decrease inflammation and edema. Anticholinergic drugs may relieve bronchospasm by blocking parasympathetic cholinergic impulses at the receptor level. Antihistamines occasionally prevent or abort allergic asthmatic episodes, particularly in children, but they can only be partially effective in asthma because histamine is only one of many mediators.

The current drug modalities used for treatment of allergy-induced asthma suffer from a number of drawbacks. In general, the conventional agents have a relatively short duration of action and may be partially or wholly ineffective when administered after antigen challenge occurs. Moreover, because of serious adverse effects associated with the use of agents such as beta<sub>2</sub>-adrenergic agonists and corticosteroids, the therapeutic margin of safety with such agents is relatively narrow and patients using them must be carefully monitored.

Bronchial hyperreactivity (or airway hyper-responsiveness) is a hallmark of asthma and is closely related to underlying airway inflammation. Worsening of asthma and airway inflammation is associated with increase in bronchial hyperreactivity, which can be induced by both antigenic and non-antigenic

stimuli. Beta<sub>2</sub>-adrenergic agonists are potent agents for the treatment of bronchospasm, but have no effect on airway inflammation or bronchial hyperreactivity. In fact, chronic use of beta<sub>2</sub>-adrenergic agents alone, by causing down regulation of beta<sub>2</sub>-receptors, may worsen bronchial hyperreactivity. At present, corticosteroids are the only effective agents available which diminish bronchial hyperreactivity. Although inhaled corticosteroids are relatively safe in adult patients with asthma, these agents have tremendous toxicity in children, including adrenal suppression and reduced bone density and growth. Thus, the search for safer and effective agents which diminish bronchial hyperreactivity continues.

It has been discovered in the past several years that heparin administered intrabronchially can be an effective inhibitor of bronchospasm and bronchoconstriction and is consequently of value in the prophylaxis of asthma (see, e.g., Ahmed et al., New Eng. J. Med., 329:90-95, 1993; Ahmed, Resp. Drug Deliv., IV:55-63, 1994). It has been discovered further that low molecular weight heparins, e.g., heparins with an average molecular weight of 4,000-5,000 daltons, effectively prevent antigen-induced bronchoconstriction; these low-weight heparins also exhibit considerably less anticoagulant activity than commercial heparin, a desirable property when these agents are used in the treatment of asthma (see Ashkin et al., Am. Rev. Resp. Dis., 1993 Intl. Conf. Abstracts, p. A660).

While various heparins have been found useful as prophylactic agents when administered prior to antigen challenge, however, they have been disclosed in the prior art as ineffective when administered after antigen challenge in modifying bronchoconstrictor response and airway hyperresponsiveness (Ahmed et al., J. Appl. Physiol., 76:893-901, 1994).

It is an object of the present invention to provide a method and compositions for treatment of antigen-induced asthma and bronchial hyperreactivity which do not suffer from the drawbacks of the prior art.

It is a further object of the present invention to provide a method and compositions for the treatment of asthma which are effective in preventing and reversing the manifestations of an asthmatic episode.

Still another object of the present invention is to provide a method and compositions as described above which are highly effective in diminishing specific and non-specific bronchial hyperreactivity, and even when administered after antigen challenge to the patient.

In keeping with these objects and others which will become apparent hereinafter, the invention resides in a method of treating a patient suffering from antigen-induced asthma through the intrabronchial administration to the patient of a pharmaceutical composition comprising from about 0.05 to about 1.0 mg of ultra-low molecular weight heparins per kilogram of patient body weight in each dose. The administration of these heparins can be on an acute basis following antigen challenge or on a chronic basis to suppress bronchial hyperreactivity.

The ultra-low molecular weight heparins used in the present invention have average molecular weights of less than 3,000 daltons and may exhibit a low level of anticoagulant activity or substantially no anticoagulant activity at all. Novel inhalant compositions are also provided in the form of liquid or powdered nebulizer or aerosol compositions containing suitable concentrations of ultra-low molecular weight heparins.

FIG. 1 is a bar graph illustrating the effect of pretreatment with inhaled ultra-low molecular weight heparin (CY222) at varying dose levels on antigen-induced acute bronchoconstriction in allergic sheep. Data are shown as antigen-induced mean  $\pm$  SE% change in  $SR_{1,}$  without and after pretreatment with CY222.

$SR_L$  = Specific lung resistance  
 + = Significantly different from antigen control ( $P < .05$ )

FIG. 2 is a bar graph illustrating the effect of pretreatment with inhaled low molecular weight heparin (CY216) on antigen-induced acute bronchoconstriction in allergic sheep. Data are shown as antigen-induced mean  $\pm$  SE% change in  $SR_L$ , without and after pretreatment with CY216.

FIG. 3 is a bar graph illustrating the effect of pretreatment with inhaled medium molecular weight heparin (Fragmin) on antigen-induced bronchoconstriction in allergic sheep. Data are shown as antigen-induced mean  $\pm$  SE% change in  $SR_L$ , without and after treatment with Fragmin.

FIG. 4 is a bar graph illustrating the effect of pretreatment with inhaled ultra-low molecular weight heparin (CY222) on antigen-induced airway hyperresponsiveness in allergic sheep. Data are shown as post-antigen mean  $\pm$  SE  $PD_4$ , as percentage of baseline, without and after pretreatment with CY222.

$PD_4$  = Cumulative provoking dose of carbachol, increasing  
 $SR_L$  to 400% above baseline  
 + = Significantly different from antigen alone ( $P < .05$ ).

FIG. 5 is a bar graph illustrating the effect of pretreatment with inhaled low molecular weight heparin (CY216) on antigen-induced airway hyperresponsiveness in allergic sheep. Data are shown as post-antigen mean  $\pm$  SE  $PD_4$ , as percentage of baseline, without and after pretreatment with CY216.

FIG. 6 is a bar graph illustrating the effect of pretreatment with inhaled medium molecular weight heparin (Fragmin) on antigen-induced airway hyperresponsiveness in allergic sheep. Data are shown as post-antigen mean  $\pm$  SE  $PD_4$ , as percentage of baseline, without and after pretreatment with Fragmin.

FIG. 7 is a graph illustrating the comparative protective effects of inhaled CY222, CY216 and Fragmin on antigen-induced acute bronchoconstrictor response (ABR) in allergic sheep. Data are shown as post-antigen mean  $\pm$  SE% protection of antigen-induced ABR. Thick horizontal bars represent ID<sub>50</sub>.

+ = Significantly different from Fragmin (P<.05)

\* = Significantly different from CY216 (P<.05).

FIG. 8 is a graph illustrating the comparative protective effects of inhaled CY222, CY216 and Fragmin on antigen-induced airway hyperresponsiveness (AIR) in allergic sheep. Data are shown as post-antigen mean  $\pm$  SE% protection of antigen-induced changes in PD<sub>4</sub>.

FIG. 9 is a bar graph illustrating the effect of CY222 on antigen-induced airway hyperresponsiveness with CY222 being administered as an aerosol immediately after antigen challenge.

+ = Significantly different from baseline (P<.05)

FIG. 10 is a bar graph illustrating the effect of commercial heparin on antigen-induced airway hyperresponsiveness with commercial heparin being administered as an aerosol immediately after antigen challenge.

FIG. 11 is a bar graph illustrating the effect of Fragmin on antigen-induced airway hyperresponsiveness with Fragmin being administered as an aerosol immediately after antigen challenge.

Heparin, a sulfated mucopolysaccharide, is synthesized in mast cells as a proteoglycan and is particularly abundant in the lungs of various animals. Heparin is not a specific compound of fixed molecular weight but is actually a heterogenous mixture of variably sulfated polysaccharide chains composed of repeating units of D-glucosamine and either L-iduronic or D-glucuronic acids. The average molecular weight of heparin isolated from animal tissues ranges from about 6,000 to about 30,000 daltons.



Pharmacologically, heparin is known primarily as an anticoagulant. This activity results from heparin's ability to bind to some of the residues of antithrombin III (AT-III), accelerating the neutralization by AT-III of activated clotting factors and preventing the conversion of prothrombin to thrombin. Larger amounts of heparin can inactivate thrombin and earlier clotting factors, preventing conversion of fibrinogen to fibrin.

The anticoagulant activity of heparin is related to the molecular weight of its polysaccharide fragments; low molecular weight components or fragments (for example, fragments having a molecular weight of less than 6,000 daltons) have moderate to low antithrombin and hemorrhagic effects. Similarly, low molecular weight heparins isolated from animal tissue have reduced anticoagulant properties because they consist primarily of the lower molecular weight fragments or fractions.

Commercial heparin, which is generally derived from beef lung or pork intestinal mucosa, has an average molecular weight of about 15,000-17,500 daltons.

Heparin has been shown to act as a specific blocker of the  $IP_3$  receptors and inhibits  $IP_3$  mediated calcium release. We have previously suggested that heparin may block  $IP_3$  receptors in mast cells and therefore by interfering with signal transduction may modulate mast cell degranulation and mediator release. *In vivo* and *in vitro* studies support this concept and have demonstrated that inhaled heparin can attenuate allergic bronchoconstriction in sheep, prevent exercise induced asthma, as well as inhibit anti IgE induced mast cell histamine release. Inhaled heparin in doses up to 1,000 units/kg has been found to have no effect on partial thromboplastin time (PTT), thus, suggesting a "non-anticoagulant" effect.

It has also been reported that low molecular weight heparins (average molecular weight about 4,500 daltons), which have reduced APTT activity, were effective in animal studies in preventing antigen-induced acute bronchoconstrictor response (ABR) and bronchial hyperreactivity, also referred to as airway-hyperresponsiveness (AHR). However, as discussed and illustrated in greater detail

below, neither commercial heparin nor medium or low molecular weight heparins, even those with very low anticoagulant activity, are effective in ameliorating AHR subsequent to antigen challenge in test subjects. These heparins apparently provide only a prophylactic, preventive effect, but are not of value in treating an antigen-triggered asthmatic episode.

It has now been discovered, surprisingly, that ultra-low molecular weight heparin (ULMWH) fractions are not only effective inhibitors of airway anaphylaxis, but are highly effective in reducing AHR even when administered after antigen challenge. Chronic, regular use of ULMWH should also reduce AHR, and ULMWH therefore may be used for chronic therapy of asthma whether caused by specific (i.e., antigenic) or non-specific factors.

Accordingly, the present invention constitutes a method of treating a patient suffering from antigen-induced asthma who has been challenged with an asthma-inducing antigen comprising the intrabronchial administration to the patient of a pharmaceutical composition containing about 0.05 to about 1.0 mg of one or more ULMWH fractions per kilogram of patient body weight in each dose of said composition, and preferably from about 0.075 to about 0.75 mg/kg per dose. For purposes of this application, ULMWH may be defined as heparin fractions having an average molecular weight of 3,000 daltons or less. ULMWH having an average molecular weight of 2,500 daltons or less may be even more effective when used in the method of the invention. Each ULMWH fraction may comprise disaccharides, trisaccharides, tetrasaccharides and/or pentasaccharides, as well as molecules of greater chain length.

In accordance with the invention, a patient suffering from antigen-induced asthma who has inhaled, ingested or otherwise come into contact with an antigen (i.e., has been "challenged" with an antigen) of a type known to provoke asthmatic episodes in that patient, whether or not the patient is already exhibiting

symptoms of ABR and/or AIR, is promptly administered via inhalation one dose of a pharmaceutical composition containing one or more ULMWH fractions cumulatively present in the above-described concentration ranges. Additional doses may subsequently be administered as necessary until the patient regains or maintains normal airflow resistance levels.

The invention also comprehends the chronic administration of ULMWH to asthma patients to reduce and suppress AIR. "Chronic administration" as used herein refers to administration of the ULMWH-containing compositions at least once daily for at least ten consecutive days. Chronic administration of a composition containing from about 0.05-1.0 mg/kg per dose, and preferably about 0.075-0.75 mg/kg per dose, can be continued indefinitely to provide AIR-suppressant therapy at least comparable to corticosteroids but substantially without side effects.

Despite the known activity of N-desulfated heparins in other biological systems, for example as inhibitors of cell growth, it has been found that ULMWH fractions which are active and can be used in the present invention for treating asthmatic patients are all N-sulfated; N-desulfated fractions are ineffective.

The inhalant ULMWH compositions used in the present invention may comprise liquid or powdered compositions containing ULMWH and suitable for nebulization and intrabronchial use, or aerosol compositions administered via an aerosol unit dispensing metered doses.

Suitable liquid compositions comprise ULMWH in an aqueous, pharmaceutically acceptable inhalant solvent, e.g., isotonic saline or bacteriostatic water. The solutions are administered by means of a pump or squeeze-actuated nebulized spray dispenser, or by any other conventional means for causing or enabling the requisite dosage amount of the liquid composition to be inhaled into the patient's lungs.

Suitable powder compositions include, by way of illustration, powdered preparations of heparin thoroughly intermixed with lactose or other inert powders acceptable for intrabronchial administration. The powder compositions can be administered via an aerosol dispenser or encased in a breakable capsule which may be inserted by the patient into a device that punctures the capsule and blows the powder out in a steady stream suitable for inhalation.

Aerosol formulations for use in the subject method would typically include fluorinated alkane propellants, surfactants and co-solvents and may be filled into aluminum or other conventional aerosol containers which are then closed by a suitable metering valve and pressurized with propellant.

The total concentration of ULMWH fractions in any vehicle suitable for use in accordance with the present invention must be sufficiently high to provide the required dose of about 0.05 to 1.0 mg of ULMWH/kg. Thus, for example, if a nebulizer administers 4 ml of solution per dose, the concentration of ULMWH in the solution in the case of a patient weighing 75 kg should be approximately 1.0 - 20.0 mg/ml.

As those skilled in the pharmaceutical arts will appreciate, many conventional methods and apparatus are available for administering precisely metered doses of intrabronchial medicaments and for regulating the desired dosage amount in accordance with patient weight and severity of the patient's condition. Moreover, there are many art-recognized liquid, powdered and aerosol vehicles suitable for the intrabronchial ULMWH compositions of the present invention. The invention is not limited to any particular inert vehicles, solvents, carriers or excipients and is not restricted to any particular methods or apparatus or intrabronchial administration.

The ULMWH compositions described herein provide highly effective treatment for antigen-induced asthma even after antigen challenge has occurred.

To demonstrate the unexpected superiority of ULMWH fractions in comparison with higher molecular weight heparins in treating antigen induced asthma after antigen challenge, experiments were conducted comparing the effects of different heparin types on allergic sheep, both before and after antigen challenge. Detailed descriptions of these experiments and of the results obtained are set forth in the following examples as well as in the figures shown in the drawings.

The following examples, while illustrating the method of the invention and demonstrating the efficacy of the same, are not intended to set forth specific materials, procedures or dosage regimens which must be utilized exclusively in order to practice the invention.

### EXAMPLE I

#### Administration of Heparins Prior to Antigen Challenge

##### Methods

##### Pulmonary Airflow Resistance:

Sixteen allergic sheep, with previously documented only acute bronchoconstrictor response to Ascaris suum antigen were used for all studies. The sheep were intubated with a cuffed nasotracheal tube and pulmonary airflow resistance ( $R_L$ ) was measured by the esophageal balloon catheter technique, while thoracic gas volume was measured by body plethysmography. Data was expressed as specific  $R_L$  ( $SR_L$ , defined as  $R_L$  times thoracic gas volume ( $V_{tg}$ )).

##### Airway Responsiveness:

To assess airway responsiveness, cumulative dose-response curves to inhaled cabachol were performed by measuring  $SR_L$  before and after inhalation of buffered saline and after each administration of 10 breaths of increasing concentrations of carbachol (0.25, 0.5, 1.0, 2.0 and 4.0% wt/vol solution). Airway

responsiveness was measured by determining the cumulative provocation dose (PD<sub>4</sub>) of carbachol (in breath units) that increased SR<sub>1</sub> to 400% above baseline. One breath unit was defined as one breath of 1% carbachol solution.

#### Heparin Fractions:

In the experiment comparing the effectiveness of various heparin materials administered to the allergic sheep prior to antigen challenge one ULMWH (CY222, Sanofi, Paris, France), one low molecular weight heparin (CY216, Sanofi) and one medium molecular weight heparin (Fragmin, Kabivitrum, Stockholm, Sweden) were used. The molecular weight and other characteristics of these \*heparin fractions are set forth in Table 1.

**TABLE 1**  
**MOLECULAR WEIGHT AND**  
**CHARACTERISTICS OF HEPARIN FRACTIONS**

	<u>CY222</u> (ULMWH)	<u>CY216</u> (LMWH)	<u>FRAGMIN</u> (MMWH)
Molecular Wt.	2355 d	4270 d	6400 d
Anti-Xa activity	70 I.U./mg	112 I.U./mg	158 I.U./mg
Anti-IIa activity	12 I.U./mg	29 I.U./mg	--
APTT	28 I.U./mg	45 I.U./mg	58 I.U./mg
Anti-Xa/APTT ratio	2.5	2.5	2.72
% GAG Content	70%	60%	65%
% of ULMW chains (m.w. < 2500d)	88%	27%	11%

As indicated in the table, the ULMWH utilized in this experiment not only has a molecular weight well below 3,000, but in addition about 88% of the heparin chains included in this fraction have molecular weights below 2,500.

### Experimental Protocol

#### Airway Studies

Each animal's baseline airway responsiveness ( $PD_4$ ) was determined, and then on different experimental days the sheep underwent airway challenge with *Ascaris suum* antigen.  $SR_L$  was measured, before and immediately after challenge, and then hourly for up to 2 hours until  $SR_L$  had returned to the baseline. The post-challenge  $PD_4$  was then measured. The protocol was repeated at least 14 days later, after pretreatment with aerosolized CY222, CY216, and Fragmin, at doses of 0.31, 0.62, 1.25, 2.5, and 5.0 mg/kg.

#### Data Analysis:

Data were expressed as (a) mean  $\pm$  SE% change of  $SR_L$ ; (b)  $PD_4$  as % of baseline; (c) % protection of acute bronchoconstrictor response (ABR) and (d) % protection of airway hyperresponsiveness (AHR).

$$(a) \quad SR_L (\% \text{ change}) = \frac{\text{post challenge } SR_L - \text{baseline } SR_L}{\text{baseline } SR_L} \times 100$$

$$(b) \quad PD_4 (\% \text{ baseline}) = \frac{\text{post challenge } PD_4}{\text{baseline } PD_4} \times 100$$

$$(c) \quad \text{ABR } \% \text{ protection} = \frac{\text{control } \Delta SR_L \% - \text{LMWHF } \Delta SR_L \%}{\text{control } \Delta SR_L \%} \times 100$$

$$(d) \quad \text{AHR } \% \text{ protection} = \frac{\text{LMWHF } PD_4 - \text{CONTROL ANTIGEN } PD_4}{\text{baseline } PD_4 - \text{control antigen } PD_4} \times 100$$

The comparative effects of pretreatment with the test materials on ABR and AHR are set forth in Tables 2-6 and are graphically illustrated in FIGS. 1-8.

The data show that pretreatment with aerosolized CY222, CY216 and Fragmin attenuated the antigen-induced acute bronchoconstrictor response in a dose dependent fashion; the minimal effective doses were 0.62 mg/kg, 1.25 mg/kg and 2.5 mg/kg, respectively.

Pretreatment with aerosolized CY222, CY216, and Fragmin attenuated the antigen-induced AHR in a dose dependent fashion; the minimal effective doses were 0.62 mg/kg, 1.25 mg/kg, and 5.0 mg/kg; respectively.

Analysis of interdrug comparison revealed that the protective effects were inversely related to the molecular weight of the heparin fractions. The ULMWH fraction, CY222, was the most potent agent, as shown by significant inhibition of antigen-induced bronchoconstriction and AHR at 0.6 mg/kg dose, while CY216 and Fragmin were ineffective at this dose. The group average values of I.D.<sub>50</sub> of CY222, CY216 and Fragmin against allergic bronchoconstriction were 0.5, 1.3 and 1.8 mg/kg, respectively. The respective group average values of I.D.<sub>50</sub> of CY222, CY216 and Fragmin against AHR were 0.51, 2.5 and 4.7 mg/kg.



**TABLE 2**  
**EFFECT OF PRETREATMENT WITH CY222 ON**  
**ANTIGEN-INDUCED BRONCHIOCONSTRICTION**

<u>ANTIGEN-CONTROL</u>			<u>CY222</u>		
<u>Dose</u> (mg/kg)	<u>Baseline</u>	<u>Post- Challenge</u>	<u>Baseline</u>	<u>Post- CY222</u>	<u>Post- Challenge</u>
0.31 (n=7)	1.15 (.04)	3.27* (.33)	1.17 (.05)	1.08 (.06)	2.66* (.35)
0.62 (n=7)	1.15 (.04)	3.27* (.33)	1.15 (.05)	1.21 (.06)	1.65+ (.06)
1.25 (n=6)	1.16 (.04)	3.43* (.32)	1.08 (.06)	1.17 (.05)	1.71+ (.19)
2.5 (n=6)	1.13 (.04)	3.31* (.39)	1.04 (.05)	1.06 (.10)	1.33+ (.09)
5.0 (n=6)	1.13 (.04)	3.31* (.39)	1.16 (.05)	1.12 (.02)	1.56+ (.12)

Data are shown as mean $\pm$ SE SR<sub>L</sub> (specific lung resistance), without and after pretreatment with increasing doses of inhaled CY222.

- \* Significantly different from baseline (P<.05)
- + Significantly different from antigen-control (P<.05)

**TABLE 3**  
**EFFECT OF PRETREATMENT WITH CY216 ON**  
**ANTIGEN-INDUCED BRONCHIOCONSTRICTION**

<u>ANTIGEN-CONTROL</u>			<u>CY216</u>		
<u>Dose</u> <u>(mg/kg)</u>	<u>Post-</u> <u>Baseline</u>	<u>Challenge</u>	<u>Baseline</u>	<u>Post-</u> <u>CY216</u>	<u>Post-</u> <u>Challenge</u>
0.31 (n=7)	0.92 (.04)	2.64* (.23)	1.12 (.07)	1.08 (.04)	3.21* (.09)
0.62 (n=7)	0.92 (.04)	2.64* (.23)	1.04 (.06)	1.07 (.03)	2.54* (.31)
1.25 (n=8)	1.12 (.04)	3.24* (.29)	1.04 (.07)	1.20 (.13)	2.03+ (.36)
2.5 (n=5)	1.14 (.05)	3.36* (.48)	1.05 (.07)	1.04 (.11)	1.76+ (.32)
5.0 (n=6)	1.09 (.04)	3.35* (.14)	1.09 (.03)	1.18 (.08)	1.75+ (.20)

Data are shown as mean $\pm$ SE SR<sub>L</sub> (specific lung resistance) without and after pretreatment with inhaled CY216.

\* Significantly different from baseline (P<.05)

+ Significantly different from antigen-control (P<.05)

TABLE 4

**EFFECT OF TREATMENT WITH FRAGMIN  
ON ANTIGEN BRONCHIOCONSTRICTION**

<u>ANTIGEN-CONTROL</u>			<u>FRAGMIN</u>		
<u>Dose</u> (mg/kg)	<u>Baseline</u>	<u>Post-Challenge</u>	<u>Baseline</u>	<u>Post-Fragmin</u>	<u>Post-Challenge</u>
1.25 (n=7)	1.04 (.06)	3.37* (.32)	1.11 (.05)	1.07 (.08)	2.71* (.42)
2.5 (n=6)	0.96 (.04)	3.19* (.30)	1.07 (.08)	1.16 (.12)	1.56+ (.25)
5.0 (n=7)	1.00 (.01)	3.39* (.39)	0.98 (.03)	0.98 (.03)	1.47+ (.21)

Data are shown as mean  $\pm$  SE  $SR_L$  (specific lung resistance), without and after pretreatment with inhaled Fragmin.

- \* Significantly different from baseline ( $P < .05$ )
- + Significantly different from antigen-control ( $P < .05$ )

**TABLE 5**  
**EFFECT OF PRETREATMENT WITH INHALED CY222, CY216 AND**  
**FRAGMIN ON ANTIGEN-INDUCED AIRWAY HYPERRESPONSIVENESS**

Dose (mg/kg)	CY222		CY216		FRAGMIN			
	BASELINE	CONTROL DRUG	BASELINE	CONTROL DRUG	BASELINE	CONTROL DRUG		
0.31 (n=7)	15.3 (0.7)	*6.7 (0.6)	*8.4 (1.9)	19.4 (2.6)	*7.3 (1.4)	10.3 (2.8)	--	--
0.62 (n=6)	15.7 (0.7)	*6.5 (0.7)	13.0+ (1.5)	19.2 (2.2)	*8.3 (1.5)	*11.3 (2.1)	--	--
1.25 (n=7)	15.4 (0.6)	*6.7 (0.6)	15.6+ (1.6)	15.3 (0.7)	*6.7 (0.6)	*10.6+ (1.3)	16.7 (1.8)	*3.7 (1.8)
2.5 (n=6)	15.7 (0.7)	*6.5 (0.7)	18.1+ (2.5)	15.4 (0.7)	*6.1 (0.7)	*10.7+ (1.7)	19.3 (3.0)	*7.8 (1.6)
5.0 (n=6)	15.7 (0.7)	*6.5 (0.7)	15.9+ (0.5)	15.7 (1.0)	*8.5 (0.7)	16.4+ (1.4)	19.4 (2.7)	*10.5 (2.1)
								16.6+ (2.9)

Data are shown as mean  $\pm$  SE PD<sub>4</sub> of carbachol in breath units, for the baseline and post-antigen, without (control) and after pretreatment (drug) with various heparin fractions.

PD<sub>4</sub> = Cumulative provoking dose of carbachol which increased SR<sub>L</sub> to 400% above baseline.

One breath unit is equivalent to one breath of 1 mg/ml carbachol.

\* Significantly different from baseline (P < .05) + Significantly different from antigen control (P < .05)

TABLE 6

COMPARISON OF PROTECTIVE EFFECTS OF INHALED CY222 (ULTRALOW MOLECULAR WEIGHT); CY216 (LOW MOLECULAR WEIGHT) AND FRAGMIN (MEDIUM MOLECULAR WEIGHT) ON ANTIGEN-INDUCED BRONCHOCONSTRICTION AND AIRWAY HYPERRESPONSIVENESS

ALLERGIC BRONCHOCONSTRICTION				AIRWAY HYPERRESPONSIVENESS			
Dose (mg/kg)	CY222	CY216	FRAGMIN	Dose (mg/kg)	CY222	CY216	FRAGMIN
0.31	11% (21%)	-16% (14%)	---	0.31	18% (21%)	32% (17%)	---
0.62	75%†* (8%)	25% (15%)	---	0.62	68%† (18%)	30% (11%)	---
1.25	78%†+ (8%)	50%† (20%)	24% (20%)	1.25	*107%†+ (26%)	48%† (12%)	21% (12%)
2.5	79%† (9%)	60%† (11%)	84%† (9%)	2.5	*131%†+ (35%)	49%† (12%)	30% (11%)
5.0	79%† (3%)	79%† (6%)	82%† (7%)	5.0	102%†+ (8%)	108%†+ (15%)	53%† (16%)
I.D. <sub>50</sub>	0.5mg/kg	1.3 mg/kg	1.8 mg/kg	I.D. <sub>50</sub>	0.5mg/kg	2.5mg/kg	4.7mg/kg

Data are shown as mean  $\pm$  SE % protection at each dose. Calculated group average I.D.<sub>50</sub> (inhibiting dose causing

50% protection) is also shown for each group.

† Significant protection ( $P < .05$ )

+ Significantly different from Fragmin ( $P < .05$ )

\* Significantly different from CY216 ( $P < .05$ )

**EXAMPLE II****Administration of Heparins Following Antigen Challenge**

The same experimental protocol was followed as in Example I, except that

(a) the three heparin materials administered to the test animals were CY222, commercial heparin (molecular weight approximately 15,000 daltons) and Fragmin, and

(b) the heparins were administered to the animals as an aerosol immediately after antigen challenge.

The test data are set forth in Table 7 and graphically illustrated in FIGS. 9-11.

**TABLE 7**

**COMPARATIVE EFFECTS OF INHALED COMMERCIAL HEPARIN (8 MG/KG), MEDIUM MOLECULAR WEIGHT HEPARIN FRACTION (FRAGMIN, 5 MG/KG) AND ULTRA LOW-MOLECULAR WEIGHT HEPARIN FRACTION (CY222, 0.6 MG/KG) ON ANTIGEN-INDUCED AIRWAY HYPERRESPONSIVENESS**

	<b>Baseline</b>	<b>Post-Antigen (control)</b>	<b>Post-Antigen (heparin)</b>
<b>Heparin</b>	18.9±2.1	10.5±0.2*	8.9±2.2*
<b>Fragmin</b>	22.7±3.2	13.3±2.0*	9.5±2.6*
<b>CY222</b>	20.4±1.7	11.7±2.1*	25.1±1.1 <sup>+</sup>

Data are shown as mean±SE PD<sub>400</sub> of carbachol in breath units (one breath unit is equivalent of one breath of 1 mg/ml carbachol). All agents were nebulized immediately "after" the antigen challenge.

- \* Significantly different from baseline (p < .05)
- + Significantly different from antigen-control (p < .05)
- Only CY222 offered significant protection

As indicated by Table 7 and FIGS. 9-11, inhaled CY222 administered after antigen challenge substantially modified post-antigen AHR, restoring AHR levels in the test subjects to baseline levels or above. This effect was not observed with commercial heparin or Fragmin, wherein no improvement in AHR resulted from post-challenge administration of these heparins.

It has thus been shown that there have been provided methods and compositions which achieve the various objects of the invention and which are well adapted to meet the conditions of practical use.

As various possible embodiments might be made of the above invention, and as various changes might be made in the embodiments set forth above, it is to be understood that all matters herein described are to be interpreted as illustrative and not in a limiting sense.

What is claimed as new and desired to be protected by Letters Patent is set forth in the following claims.

**CLAIMS:**

1. A method of treating a patient suffering from antigen-induced asthma who has been challenged with an asthma-inducing antigen comprising intrabronchial administration to the patient of a pharmaceutical composition containing about 0.05 to about 1.0 mg of ultra-low molecular weight heparins (ULMWH) per kilogram of patient body weight in each dose, said ULMWH having an average molecular weight of 3,000 daltons or less.
2. A method according to claim 1 wherein said ULMWH have an average molecular weight of 2,500 daltons or less.
3. A method according to claim 1 wherein said composition contains about 0.075 to about 0.75 mg of ULMWH per kilogram per dose.
4. A method according to claim 1 wherein said composition contains about 1.0 to about 20.0 mg of ULMWH per ml of composition.
5. A method according to claim 1 wherein said ULMWH have substantially no anticoagulant activity.
6. A method according to claim 1 wherein each of said ULMWH comprises disaccharides, trisaccharides, tetrasaccharides or pentasaccharides.
7. A method according to claim 1 wherein said composition comprises a solution of ULMWH in an aqueous, pharmaceutically acceptable inhalant vehicle.
8. A method according to claim 7 wherein said vehicle is isotonic saline or bacteriostatic water.
9. A method according to claim 7 wherein said composition is administered by means of a pump or squeeze-actuated nebulizer.
10. A method according to claim 7 wherein said composition further includes an aerosol propellant and is administered via a metered aerosol dose inhaler.



11. A method according to claim 1 wherein said composition comprises a powdered preparation of ULMWH intermixed with an inert powder acceptable for intrabronchial administration.

12. A method according to claim 11 wherein said inert powder is lactose.

13. A method according to claim 11 wherein said composition is administered via an aerosol dispenser.

14. A method according to claim 11 wherein said composition is administered from a breakable capsule.

15. A method of treating a patient suffering from asthma to reduce and suppress airway hyperresponsiveness comprising intrabronchial administration on a chronic basis to the patient of a pharmaceutical composition containing about 0.05 to about 1.0 mg of ultra-low molecular weight heparins (ULMWH) per kilogram of patient body weight in each dose, said ULMWH having an average molecular weight of 3,000 daltons or less.

16. A method according to claim 15 wherein said ULMWH have an average molecular weight of 2,500 daltons or less.

17. A method according to claim 15 wherein said composition contains about 0.075 to about 0.75 mg of ULMWH per kilogram per dose.

18. A method according to claim 15 wherein said composition contains about 1.0 to about 20.0 mg of ULMWH per ml of composition.

19. A method according to claim 15 wherein said ULMWH have substantially no anticoagulant activity.

20. A method according to claim 15 wherein each of said ULMWH comprises disaccharides, trisaccharides, tetrasaccharides or pentasaccharides.

21. A pharmaceutical composition for the treatment of a patient suffering from antigen-induced asthma comprising about 0.05 to about 1.0 mg of ULMWH per kilogram of patient body weight in each dose in a pharmaceutically acceptable inhalant vehicle, said ULMWH having an average molecular weight of 3,000 daltons or less.

22. A composition according to claim 21 wherein said ULMWH have an average molecular weight of 2,500 daltons or less.

23. A composition according to claim 21 which comprises about 0.075 to about 0.75 of ULMWH per kilogram per dose.

24. A composition according to claim 21 which contains about 1.0 to about 20.0 mg of ULMWH per ml of composition.

25. A composition according to claim 21 where said ULMWH have substantially no anticoagulant activity.

26. A composition according to claim 21 wherein each of said ULMWH comprises disaccharides, trisaccharides, tetrasaccharides or pentasaccharides.

27. A composition according to claim 21 which comprises a solution of ULMWH in an aqueous, pharmaceutically acceptable inhalant vehicle.

28. A composition according to claim 27 wherein said vehicle is isotonic saline or bacteriostatic water.

29. A composition according to claim 27 which is suitable for administration by means of a pump or squeeze-actuated nebulizer.

30. A composition according to claim 27 which further includes an aerosol propellant and is suitable for administration via a metered aerosol dose inhaler.


31. A composition according to claim 27 which comprises a powdered preparation of ULMWH intermixed with an inert powder acceptable for intrabronchial administration.

32. A composition according to claim 31 wherein said inert powder is lactose.

33. A composition according to claim 31 which is administered via an aerosol dispenser.

34. A composition according to claim 31 which is administered from a breakable capsule.

FIG. 1



2/11

FIG. 2





FIG.3







FIG. 4

SUBSTITUTE SHEET (RULE 26)


FIG. 5



SUBSTITUTE SHEET (RULE 26)




FIG. 6



SUBSTITUTE SHEET (RULE 26)

7/11


FIG. 7



SUBSTITUTE SHEET (RULE 26)


8/11

FIG. 8




SUBSTITUTE SHEET (RULE 26)

9/11




SUBSTITUTE SHEET (RULE 26)



III/III

FIG. II



SUBSTITUTE SHEET (RULE 26)

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/13133

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>																				
IPC(6) : A61K 9/12 US CL : 424/45 According to International Patent Classification (IPC) or to both national classification and IPC																				
<b>B. FIELDS SEARCHED</b>																				
Minimum documentation searched (classification system followed by classification symbols) U.S. : 424/46																				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched NONE																				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) NONE																				
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>																				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																		
Y	ASHKIN, et al. The effect of low molecular weight heparin on antigen-induced bronchoconstriction and airway hyperresponsiveness in sheep. Am. Rev. Resp. Dis. 1993, Vol. 147, No. 4, page A660.	1-34																		
Y	AHMED, Inhaled heparin: an anti-allergic (anti-astmatic) agent. Resp. Drug Delivery IV. 1994, pages 55-63.	1-34																		
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																				
<table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>*T</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>*A* document defining the general state of the art which is not considered to be part of particular relevance</td> <td>*X*</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>*E* earlier document published on or after the international filing date</td> <td>*Y*</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>*Z*</td> <td>document member of the same patent family</td> </tr> <tr> <td>*O* document referring to an oral disclosure, use, exhibition or other means</td> <td></td> <td></td> </tr> <tr> <td>*P* document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A* document defining the general state of the art which is not considered to be part of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*E* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family	*O* document referring to an oral disclosure, use, exhibition or other means			*P* document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																		
*A* document defining the general state of the art which is not considered to be part of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																		
*E* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																		
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family																		
*O* document referring to an oral disclosure, use, exhibition or other means																				
*P* document published prior to the international filing date but later than the priority date claimed																				
Date of the actual completion of the international search 12 SEPTEMBER 1996		Date of mailing of the international search report 02 OCT 1996																		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer RAJ BAWA, Ph.D. Telephone No. (703) 308-2351																		

Form PCT/ISA/210 (second sheet)(July 1992)\*

**THIS PAGE BLANK (USPTO)**